NCT07117422招募中不适用
Efficacy and Safety of Venetoclax Plus Decitabine in Elderly/Unfit Patients With Newly Diagnosed AML: A Multicenter Single-Arm Study
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- the Complete Remission (CR) Rate after Cycle 1
研究概览
简要总结
Acute myeloid leukemia (AML) is a highly fatal malignancy in China, with particularly poor outcomes in elderly patients. Low-intensity regimens yield low remission rates, and median overall survival (OS) typically remains under 6-9 months. Venetoclax (VEN) combined with hypomethylating agents (azacitidine or decitabine（DEC）) has emerged as a first-line therapy for these patients, significantly improving response rates and survival. However, challenges persist, including suboptimal complete remission (CR) rates, low Measurable Residual Disease（MRD） negativity, and tolerability issues with prolonged use.
Recent studies suggest that a 3-day decitabine regimen combined with VEN may enhance efficacy and tolerability. Building on prior evidence and our institutional experience, we propose this study to evaluate an optimized dosing strategy of VEN plus decitabine in treatment-naïve elderly or chemotherapy-ineligible AML patients, aiming to further improve clinical outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients meeting the World Health Organization (WHO) 2022 diagnostic criteria for acute myeloid leukemia (AML), excluding:Acute promyelocytic leukemia (APL)
- •AML with recurrent genetic abnormalities, including:t(8;21)(RUNX1::RUNX1T1)
- •inv(16)(p13.1q22) or t(16;16)(p13.1q22)/CBFβ::MYH11
- •Patients classified as AML, not otherwise specified (NOS) per WHO criteria, excluding:Acute panmyelosis with myelofibrosis 、Myeloid sarcoma
- •Age and fitness criteria:
- •Group A: Age ≥65 years (unwilling to receive intensive chemotherapy)
- •Group B: Age >18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following:ECOG performance status 2 or 3；History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤65% or FEV1 ≤65%Creatinine clearance ≥30 mL/min but ≤45 mL/min (Cockcroft-Gault or 24-hour urine collection)、Any other condition deemed incompatible with standard chemotherapy (requires PI approval)
- •No prior AML therapy, except:Hydroxyurea、Low-dose cytarabine (<1.0 g/day)
- •ECOG performance status ≤3
- •Laboratory requirements (within 7 days prior to treatment):AST/ALT/ALP ≤3×ULN (≤5×ULN if due to leukemic involvement)、Total bilirubin ≤2×ULN、Cardiac enzymes <2×ULN、Serum creatinine clearance ≥30 mL/min (measured or calculated)
- •Contraception requirements:Negative pregnancy test (within 72 hours before treatment) for women of childbearing potential；Agreement to use effective contraception during treatment and for 3 years after therapy
- •Life expectancy ≥2 months
- •Informed consent:Signed by patient, legal guardian, or immediate family member (if patient is unable to consent due to medical condition)
排除标准
- •AML with BCR::ABL1 fusion or chronic myeloid leukemia (CML) in blast crisis.
- •Previously treated AML patients (received prior induction chemotherapy, regardless of response).
- •Secondary AML, including:Therapy-related AML (per WHO classification)、AML with prior history of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN)
- •Concurrent hematologic disorders (e.g., hemophilia, myelofibrosis, or other conditions deemed ineligible by the investigator). Exception: Patients with prior blood count abnormalities but confirmed non-MDS/MPN by bone marrow examination may be included.
- •Pregnant or lactating women.
- •Hypersensitivity to any study drugs.
- •Use of strong/moderate CYP3A4 inducers within 3 days prior to treatment initiation.
- •Active malignancy in other organs (requiring treatment).
- •Clinically significant hepatic/renal dysfunction exceeding inclusion criteria limits.
- •Active cardiac disease, defined as ≥1 of the following:Myocardial infarction within 6 months before enrollment；History of symptomatic arrhythmia requiring medication；Uncontrolled/symptomatic congestive heart failure (NYHA Class >2)
- •Active infections, including:Untreated tuberculosis or pulmonary aspergillosis
- •Known HIV, active hepatitis B (HBV), or hepatitis C (HCV)
- •Central nervous system (CNS) leukemia at baseline.
- •Medical history of:Epilepsy requiring medication、Dementia or psychiatric disorders impairing protocol compliance
- •Conditions limiting oral drug absorption (e.g., malabsorption syndrome).
- •Investigator's discretion for ineligibility.
研究组 & 干预措施
VEN+DEC
Experimental
干预措施: VEN + DEC (Drug)
结局指标
主要结局
the Complete Remission (CR) Rate after Cycle 1
时间窗: up to 42 days after treatment
次要结局
- Overall Survival (OS)(Within 5 years after randomization)
- Relapse-Free Survival Rate (RFS)(Within 5 years after randomization)
- Cumulative incidence of relapse(Within 5 years after randomization)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AMLAML (Acute Myelogenous Leukemia)NCT06635681Institute of Hematology & Blood Diseases Hospital, China1,200
招募中
不适用
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaAcute Myeloid LeukemiaNCT05587049AbbVie70
招募中
4 期
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaAcute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Myeloid LeukemiaNCT07044687AbbVie100
进行中（未招募）
4 期
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaAcute Myeloid Leukemia (AML)NCT05144243AbbVie44
已完成
不适用
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)NCT04826523AbbVie150